Home Cart Sign in  
Chemical Structure| 891494-63-6 Chemical Structure| 891494-63-6

Structure of SCH900776
CAS No.: 891494-63-6

Chemical Structure| 891494-63-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SCH 900776 (MK-8776) is a selective and highly potent CHK1 inhibitor with IC50 value of 3nM, modest to CDK2 and Chk2 with much higher IC50 values of 160nM and 1.5uM, respectively.

Synonyms: MK-8776

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SCH900776

CAS No. :891494-63-6
Formula : C15H18BrN7
M.W : 376.25
SMILES Code : NC1=C(Br)C([C@H]2CNCCC2)=NC3=C(C4=CN(C)N=C4)C=NN13
Synonyms :
MK-8776
MDL No. :MFCD20922873
InChI Key :GMIZZEXBPRLVIV-SECBINFHSA-N
Pubchem ID :46239015

Safety of SCH900776

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SCH900776

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK2

    CDK2, IC50:0.16 μM

  • Chk1

    Chk1, IC50:3 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
OVCAR-8 cells 0.3 µM 8 days MK-8776 selectively sensitized cells to gemcitabine but not the other agents. PMC3687010
SKOV3 cells 0.3 µM 4 hours MK-8776 enhanced sensitivity to gemcitabine. PMC3687010
MDA-MB-231 100–400 nmol/L 1 to 1.5 hours Increased radiation-induced DNA damage, inhibited cell proliferation and increased radiosensitivity of the three TNBC cell lines PMC5386307
BT-549 100–400 nmol/L 1 to 1.5 hours Increased radiation-induced DNA damage, inhibited cell proliferation and increased radiosensitivity of the three TNBC cell lines PMC5386307
CAL-51 100–400 nmol/L 1 to 1.5 hours Increased radiation-induced DNA damage, inhibited cell proliferation and increased radiosensitivity of the three TNBC cell lines PMC5386307
IMR-32 cells 1 μM 48 h To evaluate the effect of SCH900776 in combination with olaparib on cell death in IMR-32 cells, the results showed that the combination treatment significantly increased cell death. PMC8553625
LAN-5 cells 1 μM 48 h To evaluate the effect of SCH900776 in combination with olaparib on cell death in LAN-5 cells, the results showed that the combination treatment significantly increased cell death. PMC8553625
HCT116 3 μM 48 hours SCH900776 significantly enhanced LA-12 or cisplatin-induced apoptosis in HCT116 cells, as demonstrated by a significant increase in phosphatidyl serine externalization, PARP, and caspase-9 cleavage. PMC5591453
HCT116 3 μM 72 hours The combination of SCH900776 and LA-12 or cisplatin further enhanced apoptosis and DNA damage in HCT116 cells after 72 hours of treatment. PMC5591453
HT-29 3 μM 48 hours SCH900776 also significantly enhanced LA-12 or cisplatin-induced apoptosis and DNA damage in HT-29 cells. PMC5591453
RKO 3 μM 48 hours SCH900776 also significantly enhanced LA-12 or cisplatin-induced apoptosis and DNA damage in RKO cells. PMC5591453
T47D cells 1 μM 24 hours To explore whether PI3K pathway-independent mechanisms further contribute to BYL719 resistance, phosphoproteomics revealed that high p21 levels promoted repair of BYL719-induced DNA damage and bypass of cellular senescence. PMC10810864
Hs578T 20 μmol/L enzalutamide + 1 μmol/L MK-8776 48 hours To validate the synergism of MK-8776 with enzalutamide, the results showed that MK-8776 and enzalutamide had significant synergistic anti-tumor effects in Hs578T cells. PMC11143519
BT549 50 μmol/L enzalutamide + 1 μmol/L MK-8776 48 hours To validate the synergism of MK-8776 with enzalutamide, the results showed that MK-8776 and enzalutamide had significant synergistic anti-tumor effects in BT549 cells. PMC11143519
HEK293T 0, 40, 80, 160, 315, 625, 1250, 2500, 5000, 10000 nM 72 hours Screening for cytotoxicity of VX-702, which showed higher toxicity in cells with deficient CYP2D6 activity. PMC11490764

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice MDA-MB-231 xenograft tumor model intraperitoneal injection 10 ng/kg body weight/day Once daily for 21 days MK-8776 significantly reduced the volume of xenograft tumors and increased radiosensitivity PMC5386307
mice IMR-32 subcutaneous xenograft model intraperitoneal injection 0.5 mg/kg or 1 mg/kg Every 3 days for 2 weeks To evaluate the tumor growth inhibitory effect of SCH900776 in combination with olaparib in IMR-32 subcutaneous xenografts, the results showed that the combination treatment significantly inhibited tumor growth. PMC8553625
BALB/c mice 4T1 subcutaneous tumor model Intravenous injection 15 or 40 mg/kg Single dose, lasting 26 days To evaluate the anti-tumor effects of HMnE&M@H nanoparticles, the results showed that HMnE&M@H significantly inhibited tumor growth and exhibited good targeting and therapeutic effects in vivo. PMC11143519

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.29mL

2.66mL

1.33mL

26.58mL

5.32mL

2.66mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories